POULVAC IBMM + ARK – POWDER FOR NEBULISER SOLUTION FOR BROILER CHICKENS

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Toimeaine:

AVIAN INFECTIOUS BRONCHITIS VIRUS STRAIN MASSACHUSETTS 1263, AVIAN INFECTIOUS BRONCHITIS VIRUS STRAIN ARKANSAS 3168

Saadav alates:

Zoetis Ireland Limited

ATC kood:

QI01AD07

INN (Rahvusvaheline Nimetus):

AVIAN INFECTIOUS BRONCHITIS VIRUS STRAIN MASSACHUSETTS 1263, AVIAN INFECTIOUS BRONCHITIS VIRUS STRAIN ARKANSAS 3168

Ravimvorm:

Powder for nebuliser solution

Retsepti tüüp:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutiline rühm:

Fowl - Chicken

Terapeutiline ala:

avian infectious bronchitis virus

Näidustused:

Immunological - Live Vaccine

Volitamisolek:

Authorised

Loa andmise kuupäev:

2013-12-09

Toote omadused

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
POULVAC IBMM + ARK – Powder for nebuliser solution for broiler
chickens.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Powder for nebuliser solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Broiler chickens.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of chickens to reduce the severity of
upper respiratory tract infections caused
by Massachusetts and 793/B/91-type strains of Avian Infectious
Bronchitis virus.
The onset of immunity is from three weeks post vaccination and lasts
for six weeks post vaccination.
Protection has also been demonstrated in the presence of maternally
derived antibody.
4.3 CONTRAINDICATIONS
Do not use in unhealthy birds.
Do not re-vaccinate birds.
Do not use during the laying period or in birds intended for laying or
breeding.
Spray vaccination should not be used if an intercurrent infection is
suspected.
Quantitative composition
ACTIVE SUBSTANCES:
GLOBAL AMOUNT PER DOSE
Avian Infectious Bronchitis Virus
10
3.3
EID
50
*
(Strain Massachusetts1263 and Strain Arkansas 3168)
*EID
50
:
Embryo infective dose 50%
EXCIPIENTS:
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_7_
_/_
_0_
_1_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_5_
_2_
_1_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Infectious Bronchitis virus